Eterna Therapeutics Launches Research To Evaluate ERNA-101's Ability To Induce And Modulate Antitumor Immunity In Ovarian And Breast Cancer Models

BenzingaDec 3 08:38 ET

Express News | Eterna: To Investigate Ability of Erna-101 to Induce, Modulate Antitumor Immunity in Ovarian Cancer, Breast Cancer Models Through Research

ReutersDec 3 08:32 ET

Eterna Therapeutics Launches Research to Evaluate Its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

GlobeNewswireDec 3 08:30 ET

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

GlobeNewswireNov 25 08:30 ET

Express News | Eterna Therapeutics Announces up to $1 Million Stock Repurchase Program

ReutersNov 25 08:30 ET

12 Health Care Stocks Moving In Monday's Pre-Market Session

BenzingaNov 18 16:05 ET